One of the most expensive assumptions in healthcare innovation is believing that a strong product automatically creates a strong market opportunity.
It is an easy trap to fall into.
A device performs well. Clinical feedback is positive. The technology solves a genuine problem. Momentum builds around the innovation and attention quickly shifts towards launch planning and commercialisation.
The difficulty is that product viability and market viability are not always the same thing.
Some of the most commercially successful healthcare products are not necessarily the most sophisticated. Equally, some highly innovative technologies never achieve the market adoption originally anticipated.
This is where market assessment becomes valuable.
Done properly, it helps organisations move beyond optimism and understand the realities of the opportunity ahead.
Healthcare innovation operates in an environment where development costs, regulatory requirements and commercial pressures are often significant.
Decisions made early in the development process can influence outcomes years later.
A market assessment helps organisations answer fundamental questions before substantial resources are committed.
Questions such as:
The objective is not to eliminate uncertainty.
The objective is to reduce avoidable risk.
Many assessments begin with market size.
How many potential customers exist?
How large is the addressable market?
What level of growth is expected?
These are useful questions, but they are rarely enough on their own.
Healthcare markets are often complex and fragmented.
A large market may still be difficult to access.
A smaller market may prove highly attractive if adoption barriers are low and customer demand is well understood.
Market size should be viewed as one component of commercial opportunity rather than the opportunity itself.
One challenge that appears frequently in healthcare is confusion around who the customer actually is.
The person using the product is not always the person purchasing it.
The individual benefiting from the outcome may have little influence over the decision.
Clinicians, procurement teams, finance departments, executives and end users may all play a role.
Each stakeholder evaluates value differently.
When conducting a market assessment, understanding these dynamics can be just as important as understanding the product itself.
Most market assessments spend considerable time evaluating demand.
Far fewer evaluate adoption risk in the same level of detail.
Yet adoption risk may ultimately have a greater influence on commercial outcomes.
Questions worth considering include:
In healthcare, the best solution does not always win.
The easiest solution to adopt often has a considerable advantage.
Competitive reviews often focus on direct competitors.
While this is important, healthcare organisations should also consider alternative approaches.
In some cases, the greatest competitor is not another product.
It is existing practice.
Healthcare professionals frequently develop workarounds, internal processes and established methods of managing clinical challenges.
Replacing these behaviours can be significantly more difficult than anticipated.
Understanding existing practice often provides more useful insight than simply comparing product features.
Evidence expectations vary considerably across healthcare markets.
Some stakeholders prioritise clinical outcomes.
Others focus on economic benefits, operational efficiencies or service delivery improvements.
A common mistake is assuming that evidence generation can be addressed later.
In reality, market assessments often help identify evidence requirements long before commercialisation begins.
This allows organisations to plan appropriately and avoid costly delays further down the track.
A good market assessment should never end with a launch forecast.
The most valuable assessments explore what happens after launch.
Questions such as:
can provide important insights into the sustainability of the opportunity.
Commercial success is rarely determined by launch activity alone.
More often, it is determined by what happens in the months and years that follow.
Medical device and health technology markets offer significant opportunities, but they also contain significant complexity.
Successful organisations recognise that market assessment is not simply an exercise in estimating market size.
It is about understanding customers, stakeholders, adoption barriers and commercial realities.
The goal is not to validate an idea.
The goal is to determine whether a genuine commercial opportunity exists.
Before asking:
“How large is the market?”
it is often worth asking:
“How likely are customers to adopt and sustain this solution in the real world?”